European Medicines Agency decision
P/0168/2012

of 26 July 2012


Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.
European Medicines Agency decision
P/0168/2012

of 26 July 2012


The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency2,

Having regard to the application submitted by GlaxoSmithKline Biologicals on 11 July 2011 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 6 July 2012, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

---

Has adopted this decision:

**Article 1**

A paediatric investigation plan for MAGE-A3 recombinant protein, powder and solvent for solution for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for MAGE-A3 recombinant protein, powder and solvent for solution for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

This decision is addressed to GlaxoSmithKline Biologicals, Rue de l'Institut 89, B-1330 Rixensart, Belgium.

Done at London, 26 July 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)
Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral
EMEA-001099-PIP02-11

Scope of the application

Active substance(s):
MAGE-A3 recombinant protein

Condition(s):
Treatment of melanoma

Pharmaceutical form(s):
Powder and solvent for solution for injection

Route(s) of administration:
Intramuscular use

Name/corporate name of the PIP applicant:
GlaxoSmithKline Biologicals

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, GlaxoSmithKline Biologicals submitted for agreement to the European Medicines Agency on 11 July 2011 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 16 August 2011.

Supplementary information was provided by the applicant on 20 April 2012. The applicant proposed modifications to the paediatric investigation plan.
Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a deferral in accordance with Article 21 of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

Langen, Germany, 6 July 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan
1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: treatment of melanoma

2.1.1. Indication(s) targeted by the PIP

Treatment of patients with resected cutaneous melanoma, whose tumour expresses MAGE-A3.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 12 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder and solvent for solution for injection.

2.1.4. Studies

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of studies</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Non-clinical</td>
<td>1</td>
<td>MAGE-A3 antigen expression in paediatric solid malignant tumours.</td>
</tr>
<tr>
<td>Clinical</td>
<td>1</td>
<td>Open-label, single-arm, uncontrolled trial to evaluate the safety and immunogenicity of adjuvanted MAGE-A3 recombinant protein in children from 12 years to less than 18 years with resected MAGE-A3-positive melanoma.</td>
</tr>
</tbody>
</table>

3. Follow-up, completion and deferral of PIP

| Concerns on potential long term safety issues in relation to paediatric use: | Yes |
| Date of completion of the paediatric investigation plan: | By December 2019 |
| Deferral for one or more studies contained in the paediatric investigation plan: | Yes |